ExcellThera   Report issue

For profit Phase 2
Founded: Montreal Canada (2016)

Organization Overview

First Clinical Trial
2018
NCT03441958
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ExcellThera | ExCellThera inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

cord blood expanded with um171 (1 trial)

ect-001-cb (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 1)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Preleukemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2